Vertex Pharmaceuticals (VRTX) Total Non-Current Liabilities (2009 - 2026)
Vertex Pharmaceuticals' quarterly Total Non-Current Liabilities came in at $5.9 billion in Q1 2026, up 8.0% year-on-year from $5.4 billion in Q1 2025, and up 2.79% quarter-over-quarter from $5.7 billion in Q4 2025.
Vertex Pharmaceuticals has reported Total Non-Current Liabilities for 18 years, with the latest figure at $5.9 billion in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 8.0% year-over-year to $5.9 billion; the trailing twelve-month figure through Mar 2026 stood at $5.9 billion (up 8.0% YoY), and the FY2025 full-year result was $5.7 billion, up 11.72% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $5.9 billion, up from $5.7 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $6.3 billion in Q3 2025, with the low at $3.2 billion in Q1 2022.
- Average Total Non-Current Liabilities over 5 years is $4.7 billion, with a median of $4.5 billion recorded in 2024.
- Year-over-year, Total Non-Current Liabilities rose 7.49% in 2022 and soared 30.66% in 2024.
- Tracing VRTX's Total Non-Current Liabilities over 5 years: stood at $3.6 billion in 2022, then grew by 20.26% to $4.3 billion in 2023, then grew by 19.59% to $5.1 billion in 2024, then climbed by 11.72% to $5.7 billion in 2025, then grew by 2.79% to $5.9 billion in 2026.
- The last three Total Non-Current Liabilities figures came in at $5.9 billion (Q1 2026), $5.7 billion (Q4 2025), and $6.3 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 746.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.87 Bn |
| Dec 31, 2025 | 5.71 Bn |
| Sep 30, 2025 | 6.31 Bn |
| Jun 30, 2025 | 5.67 Bn |
| Mar 31, 2025 | 5.43 Bn |
| Dec 31, 2024 | 5.11 Bn |
| Sep 30, 2024 | 5.68 Bn |
| Jun 30, 2024 | 4.48 Bn |
| Mar 31, 2024 | 4.52 Bn |
| Dec 31, 2023 | 4.27 Bn |
| Sep 30, 2023 | 4.34 Bn |
| Jun 30, 2023 | 4.12 Bn |
| Mar 31, 2023 | 3.82 Bn |
| Dec 31, 2022 | 3.55 Bn |
| Sep 30, 2022 | 3.55 Bn |
| Jun 30, 2022 | 3.52 Bn |
| Mar 31, 2022 | 3.17 Bn |
| Dec 31, 2021 | 3.03 Bn |
| Sep 30, 2021 | 2.98 Bn |
| Jun 30, 2021 | 2.84 Bn |
| Mar 31, 2021 | 2.95 Bn |
| Dec 31, 2020 | 2.88 Bn |
| Sep 30, 2020 | 2.98 Bn |
| Jun 30, 2020 | 2.51 Bn |
| Mar 31, 2020 | 2.25 Bn |
| Dec 31, 2019 | 2.15 Bn |
| Sep 30, 2019 | 2.09 Bn |
| Jun 30, 2019 | 1.96 Bn |
| Mar 31, 2019 | 1.81 Bn |
| Dec 31, 2018 | 1.70 Bn |
| Sep 30, 2018 | 1.66 Bn |
| Jun 30, 2018 | 1.59 Bn |
| Mar 31, 2018 | 1.49 Bn |
| Dec 31, 2017 | 1.48 Bn |
| Sep 30, 2017 | 1.37 Bn |
| Jun 30, 2017 | 1.39 Bn |
| Mar 31, 2017 | 1.26 Bn |
| Dec 31, 2016 | 1.56 Bn |
| Sep 30, 2016 | 1.40 Bn |
| Jun 30, 2016 | 1.35 Bn |
| Mar 31, 2016 | 1.37 Bn |
| Dec 31, 2015 | 1.40 Bn |
| Sep 30, 2015 | 1.32 Bn |
| Jun 30, 2015 | 1.28 Bn |
| Mar 31, 2015 | 1.14 Bn |
| Dec 31, 2014 | 1.23 Bn |
| Sep 30, 2014 | 1.23 Bn |
| Jun 30, 2014 | 929.89 Mn |
| Mar 31, 2014 | 954.20 Mn |
| Dec 31, 2013 | 948.57 Mn |
| Sep 30, 2013 | 1.09 Bn |
| Jun 30, 2013 | 1.02 Bn |
| Mar 31, 2013 | 1.40 Bn |
| Dec 31, 2012 | 1.51 Bn |
| Sep 30, 2012 | 1.43 Bn |
| Jun 30, 2012 | 1.33 Bn |
| Mar 31, 2012 | 1.22 Bn |
| Dec 31, 2011 | 1.23 Bn |
| Sep 30, 2011 | 1.35 Bn |
| Jun 13, 2011 | -682,000.00 |
| Mar 31, 2011 | 1.14 Bn |
| Dec 31, 2010 | 1.22 Bn |
| Sep 30, 2010 | 1.23 Bn |
| Jun 30, 2010 | 825.13 Mn |
| Mar 31, 2010 | 740.31 Mn |
| Dec 31, 2009 | 857.28 Mn |